NO20034782D0 - Farmasöytisk aktive uridinestere - Google Patents

Farmasöytisk aktive uridinestere

Info

Publication number: NO20034782D0
Authority: NO; Norway
Prior art keywords: pharmaceutically active; uridine esters; active uridine; esters; deoxyuridine
Prior art date: 2001-04-30

Application number

NO20034782A

Other languages

English (en)

Other versions

NO20034782L (no

NO326964B1 (no

Inventor

Rudy Susilo

Original Assignee

Trommsdorff Arzneimittel

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-30

Filing date

2003-10-24

Publication date

2003-10-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27440125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20034782(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-10-24 Application filed by Trommsdorff Arzneimittel filed Critical Trommsdorff Arzneimittel

2003-10-24 Publication of NO20034782D0 publication Critical patent/NO20034782D0/no

2003-12-12 Publication of NO20034782L publication Critical patent/NO20034782L/no

2009-03-23 Publication of NO326964B1 publication Critical patent/NO326964B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Child & Adolescent Psychology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)

NO20034782A 2001-04-30 2003-10-24 Farmasoytisk aktive uridinestere, anvendelser derav, fremgangsmate for fremstilling derav samt farmasoytisk sammensetning inneholdende slike forbindelser NO326964B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP01110608		2001-04-30
US28809001P	2001-05-03	2001-05-03
EP01124879		2001-10-18
US33042901P	2001-10-22	2001-10-22
PCT/EP2002/004725 WO2002088159A1 (en)	2001-04-30	2002-04-29	Pharmaceutically active uridine esters

Publications (3)

Publication Number	Publication Date
NO20034782D0 true NO20034782D0 (no)	2003-10-24
NO20034782L NO20034782L (no)	2003-12-12
NO326964B1 NO326964B1 (no)	2009-03-23

Family

ID=27440125

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20034782A NO326964B1 (no)	2001-04-30	2003-10-24	Farmasoytisk aktive uridinestere, anvendelser derav, fremgangsmate for fremstilling derav samt farmasoytisk sammensetning inneholdende slike forbindelser
NO20082222A NO20082222L (no)	2001-04-30	2008-05-14	Anvendelse av legemiddelkombinasjon innbefattende minst en fettsyre og minst en nukleosid- og/eller nukleotidforbindelse

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20082222A NO20082222L (no)	2001-04-30	2008-05-14	Anvendelse av legemiddelkombinasjon innbefattende minst en fettsyre og minst en nukleosid- og/eller nukleotidforbindelse

Country Status (25)

Country	Link
EP (2)	EP1666092A3 (no)
KR (1)	KR100660754B1 (no)
CN (1)	CN1505636A (no)
AT (1)	ATE433989T1 (no)
AU (2)	AU2002308068B2 (no)
BG (1)	BG108299A (no)
BR (1)	BR0209320A (no)
CA (2)	CA2594883A1 (no)
CZ (1)	CZ20032957A3 (no)
DE (1)	DE60232653D1 (no)
DK (1)	DK1390378T3 (no)
EE (1)	EE05434B1 (no)
ES (1)	ES2327397T3 (no)
HR (1)	HRP20030879A2 (no)
HU (1)	HUP0400732A3 (no)
IL (1)	IL158006A0 (no)
IS (1)	IS6997A (no)
MX (1)	MXPA03009737A (no)
NO (2)	NO326964B1 (no)
NZ (2)	NZ546060A (no)
PL (1)	PL209031B1 (no)
PT (1)	PT1390378E (no)
SK (1)	SK287423B6 (no)
UA (1)	UA74250C2 (no)
WO (1)	WO2002088159A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8030294B2 (en)	2000-03-16	2011-10-04	The Mclean Hospital Corporation	Compounds for the treatment of psychiatric or substance abuse disorders
NL1019368C2 (nl) *	2001-11-14	2003-05-20	Nutricia Nv	Preparaat voor het verbeteren van receptorwerking.
KR20060026426A (ko) *	2003-06-19	2006-03-23	에프. 호프만-라 로슈 아게	4'-아지도 뉴클레오사이드 유도체의 제조 방법
WO2005086619A2 (en) *	2003-10-08	2005-09-22	The Mclean Hospital Corporation	Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
JP2007509994A (ja) *	2003-11-03	2007-04-19	コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	アシルリボヌクレオシドおよびアシルデオキシリボヌクレオシド
WO2006020703A1 (en)	2004-08-11	2006-02-23	The Mclean Hospital Corporation	Compounds for the treatment of marihuana dependence, withdrawal, and usage
JP2008527002A (ja) *	2005-01-13	2008-07-24	サートリスファーマシューティカルズ，インコーポレイテッド	神経変性障害および血液凝固障害を予防および処置するための新規組成物
GB0514463D0 (en) *	2005-01-31	2005-08-17	Loders Croklaan Bv	Use of pinolenic acid
WO2009002148A1 (en)	2007-06-27	2008-12-31	N.V. Nutricia	Food composition for prodromal dementia patients
CA2692309C (en) *	2007-06-26	2016-08-16	N.V. Nutricia	Improving memory in subjects with mini-mental state examination of 24-26
WO2009002146A1 (en) *	2007-06-26	2008-12-31	N.V. Nutricia	Supporting activities of daily living
WO2009002145A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Lipid composition for improving function of brain functioning
US9296776B2 (en)	2007-07-09	2016-03-29	Eastern Virginia Medical School	Substituted nucleoside derivatives with antiviral and antimicrobial properties
WO2009057994A1 (en) *	2007-11-02	2009-05-07	N.V. Nutricia	Unit dosage for brain health
ES2411726T3 (es)	2007-12-20	2013-07-08	N.V. Nutricia	Producto líquido que contiene nucleótidos/nucleósidos
US8257722B2 (en)	2008-09-15	2012-09-04	Cv Ingenuity Corp.	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en)	2008-09-15	2012-02-14	Cv Ingenuity Corp.	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en)	2008-09-15	2015-12-01	The Spectranetics Corporation	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
WO2012091542A1 (en)	2010-12-28	2012-07-05	N.V. Nutricia	Combination of components for the prevention and treatment of frailty
US9956385B2 (en)	2012-06-28	2018-05-01	The Spectranetics Corporation	Post-processing of a medical device to control morphology and mechanical properties
CN105916872A (zh) *	2013-10-23	2016-08-31	坎姆根公司	二硫戊环官能化的核苷亚酰胺和用于在固体表面上更牢固固定生物分子的载体
WO2015084158A1 (en)	2013-12-06	2015-06-11	N.V. Nutricia	A pyrimidine derivative and a fatty acid source for use in the treatment of constipation
WO2016053085A1 (en)	2014-09-30	2016-04-07	N.V. Nutricia	Composition comprising a uridine source and butyrate producing fibres for preventing gastrointestinal disorders
US20190022116A1 (en)	2014-12-26	2019-01-24	Emory University	N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
DE202015105351U1 (de)	2015-10-09	2016-01-07	Apotheke am Schlossplatz Inh. Mario Ganster e.K.	Diätetische Zusammensetzung
WO2017069611A1 (en)	2015-10-23	2017-04-27	N.V. Nutricia	Nutritional product for decreasing phenylalanine levels in pku patients
WO2017069613A1 (en)	2015-10-23	2017-04-27	N.V. Nutricia	Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
WO2017155387A1 (en)	2016-03-08	2017-09-14	N.V. Nutricia	Method for supporting memory function and/or cognitive function
WO2017155386A1 (en) *	2016-03-08	2017-09-14	N.V. Nutricia	Method for treating brain atrophy
DK3706762T3 (da)	2017-12-07	2024-12-16	Univ Emory	N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
TW202317144A (zh)	2021-06-14	2023-05-01	美商維納拓爾斯製藥公司	口服生物可利用的核苷類似物
CN114591386B (zh) *	2022-05-10	2022-09-09	深圳厚存纳米药业有限公司	一种含尿苷衍生物的纳米粒、核酸纳米复合物及其制备方法和用途
CN119504664B (zh) *	2025-01-17	2025-06-24	广东医科大学附属医院	二十碳五烯酸衍生物及其制备方法和应用、防治神经系统疾病药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5736531A (en) *	1987-10-28	1998-04-07	Pro-Neuron, Inc.	Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
EP0367724B1 (en) *	1988-10-31	1993-02-10	Sandoz Nutrition Ltd.	Improvements in or relating to organic compounds
IT1241984B (it) *	1990-06-13	1994-02-02	Polifarma Spa	Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
DE4218572A1 (de) *	1992-06-05	1993-12-09	Asta Medica Ag	Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE4343593C2 (de) *	1993-12-21	1998-05-20	Asta Medica Ag	Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
EP0871489A1 (en) *	1995-10-12	1998-10-21	Gs Development Ab	A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
JP3627043B2 (ja) *	1996-04-24	2005-03-09	明治乳業株式会社	ｎ−６系列／ｎ−３系列脂肪酸バランス改善ヌクレオチド含有乳児用食品
IT1290781B1 (it) *	1996-05-28	1998-12-10	Polifarma Spa	Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
JPH10327804A (ja) *	1997-06-04	1998-12-15	Meiji Milk Prod Co Ltd	核酸関連物質、ｄｈａ、アラキドン酸及びコレステロール含有栄養組成物
JP3820805B2 (ja) *	1999-07-08	2006-09-13	株式会社ノエビア	皮膚外用剤

2002
- 2002-04-29 NZ NZ546060A patent/NZ546060A/en not_active IP Right Cessation
- 2002-04-29 KR KR1020037014215A patent/KR100660754B1/ko not_active Expired - Fee Related
- 2002-04-29 PT PT02766645T patent/PT1390378E/pt unknown
- 2002-04-29 CZ CZ20032957A patent/CZ20032957A3/cs unknown
- 2002-04-29 EP EP05017150A patent/EP1666092A3/en not_active Withdrawn
- 2002-04-29 EP EP02766645A patent/EP1390378B1/en not_active Revoked
- 2002-04-29 NZ NZ528634A patent/NZ528634A/en not_active IP Right Cessation
- 2002-04-29 CA CA002594883A patent/CA2594883A1/en not_active Abandoned
- 2002-04-29 UA UA2003109720A patent/UA74250C2/uk unknown
- 2002-04-29 IL IL15800602A patent/IL158006A0/xx unknown
- 2002-04-29 ES ES02766645T patent/ES2327397T3/es not_active Expired - Lifetime
- 2002-04-29 AU AU2002308068A patent/AU2002308068B2/en not_active Ceased
- 2002-04-29 DK DK02766645T patent/DK1390378T3/da active
- 2002-04-29 HU HU0400732A patent/HUP0400732A3/hu unknown
- 2002-04-29 AT AT02766645T patent/ATE433989T1/de active
- 2002-04-29 WO PCT/EP2002/004725 patent/WO2002088159A1/en not_active Ceased
- 2002-04-29 DE DE60232653T patent/DE60232653D1/de not_active Expired - Lifetime
- 2002-04-29 PL PL363178A patent/PL209031B1/pl not_active IP Right Cessation
- 2002-04-29 BR BR0209320-0A patent/BR0209320A/pt not_active IP Right Cessation
- 2002-04-29 EE EEP200300536A patent/EE05434B1/xx not_active IP Right Cessation
- 2002-04-29 HR HR20030879A patent/HRP20030879A2/xx not_active Application Discontinuation
- 2002-04-29 CN CNA028091604A patent/CN1505636A/zh active Pending
- 2002-04-29 CA CA002445861A patent/CA2445861A1/en not_active Abandoned
- 2002-04-29 SK SK1341-2003A patent/SK287423B6/sk not_active IP Right Cessation
- 2002-04-29 MX MXPA03009737A patent/MXPA03009737A/es active IP Right Grant
2003
- 2003-10-21 IS IS6997A patent/IS6997A/is unknown
- 2003-10-24 NO NO20034782A patent/NO326964B1/no not_active IP Right Cessation
- 2003-10-29 BG BG108299A patent/BG108299A/bg unknown
2006
- 2006-03-01 AU AU2006200874A patent/AU2006200874A1/en not_active Abandoned
2008
- 2008-05-14 NO NO20082222A patent/NO20082222L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2594883A1 (en)	2002-11-07
WO2002088159A1 (en)	2002-11-07
CA2445861A1 (en)	2002-11-07
BR0209320A (pt)	2004-07-20
HUP0400732A2 (hu)	2004-06-28
PL363178A1 (en)	2004-11-15
HRP20030879A2 (en)	2005-08-31
HUP0400732A3 (en)	2007-05-29
SK13412003A3 (sk)	2004-05-04
NO20034782L (no)	2003-12-12
NZ528634A (en)	2005-04-29
CZ20032957A3 (cs)	2004-02-18
EP1390378A1 (en)	2004-02-25
DE60232653D1 (de)	2009-07-30
AU2006200874A1 (en)	2006-03-23
EP1666092A3 (en)	2006-11-29
IS6997A (is)	2003-10-21
PT1390378E (pt)	2009-07-23
BG108299A (bg)	2004-09-30
ATE433989T1 (de)	2009-07-15
CN1505636A (zh)	2004-06-16
MXPA03009737A (es)	2005-03-07
NZ546060A (en)	2006-11-30
EP1390378B1 (en)	2009-06-17
AU2002308068B2 (en)	2006-06-15
NO326964B1 (no)	2009-03-23
EE05434B1 (et)	2011-06-15
SK287423B6 (sk)	2010-09-07
EP1666092A2 (en)	2006-06-07
PL209031B1 (pl)	2011-07-29
KR100660754B1 (ko)	2006-12-26
DK1390378T3 (da)	2009-09-14
IL158006A0 (en)	2004-03-28
KR20040016859A (ko)	2004-02-25
EE200300536A (et)	2004-02-16
UA74250C2 (uk)	2005-11-15
ES2327397T3 (es)	2009-10-29
NO20082222L (no)	2003-12-12

Publication	Publication Date	Title
ATE433989T1 (de)	2009-07-15	Pharmazeutisch wirksame uridinester
HN1999000045A (es)	1999-08-31	Derivados biciclicos del acido hidroxamico
DE60143393D1 (de)	2010-12-16	Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
BR0111438A (pt)	2003-06-17	Análogos de ácido barbitúrico como agentes terapeuticos
BR0116026A (pt)	2004-12-21	Imidazoquinolinas substituìdas por tioéter
NO20042596L (no)	2004-06-21	Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
BR0011448A (pt)	2004-12-14	Imidazoquinolinas substituìdas por amida
DE69937198D1 (de)	2007-11-08	Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
IL190905A0 (en)	2008-11-03	4-alkoxy cyclohexane-1-amino carboxylic acids and processes for their prepatation
SE0001899D0 (sv)	2000-05-22	New compounds
SE9903759D0 (sv)	1999-10-18	Pharmaceutically active compounds
ATE504294T1 (de)	2011-04-15	Nichtnukleosidische reverse-transkriptase-hemmer
BRPI0418133A2 (pt)	2009-03-24	pró-fármaco de florfenicol tendo solubilidade em água melhorada
BR9914044A (pt)	2001-12-04	ésteres tetrahidropirido
ES2195344T3 (es)	2003-12-01	Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
ATE277929T1 (de)	2004-10-15	Immunsuppressive wirkungen von pteridinderivaten
CY1112962T1 (el)	2016-04-13	1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων
NO20034204D0 (no)	2003-09-22	Farmasöytiske kombinasjoner til behandling av kreft
YU76503A (sh)	2006-05-25	Farmaceutski aktivni estri uridina
WO2004085682A3 (de)	2005-03-31	Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza
BR0311642A (pt)	2005-03-01	Formulação de divalproex de sódio de liberação aumentada
WO2004039326A3 (en)	2004-08-12	Propofol with cysteine
SE0004101D0 (sv)	2000-11-09	New use
ATE311891T1 (de)	2005-12-15	Cytidin-diphosphocholin gegen diabetische neuropathie
GT200100184A (es)	2002-04-22	Amidas de acido fenilciclohexanocarboxilico sustituido y su uso.

Legal Events

Date	Code	Title	Description
2013-12-02	MM1K	Lapsed by not paying the annual fees